KRAS and non-small cell lung carcinoma: Since KRAS mutation is reported to be associated with resistance to multiple therapies and poor prognosis in NSCLC, several preclinical and clinical studies have investigated effective therapies, including immunotherapy and targeted therapy[6,7].